{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T01:30:49Z","timestamp":1792114249191,"version":"4.4.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2025,6,18]],"date-time":"2025-06-18T00:00:00Z","timestamp":1750204800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,6,18]],"date-time":"2025-06-18T00:00:00Z","timestamp":1750204800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82172759"],"award-info":[{"award-number":["82172759"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"DOI":"10.1007\/s00262-025-04070-8","type":"journal-article","created":{"date-parts":[[2025,6,18]],"date-time":"2025-06-18T01:08:03Z","timestamp":1750208883000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Extracellular vesicles derived from mature dendritic cells loaded with cDC1-specific chemokine XCL1 combined with chemotherapy-induced ICD for the treatment of castration-resistant prostate cancer"],"prefix":"10.1007","volume":"74","author":[{"given":"Zhongqiang","family":"Fan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shimiao","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoqiang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,18]]},"reference":[{"issue":"2","key":"4070_CR1","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.eururo.2023.04.021","volume":"84","author":"O Bergengren","year":"2023","unstructured":"Bergengren O et al (2023) 2022 update on prostate cancer epidemiology and risk factors-a systematic review. Eur Urol 84(2):191\u2013206","journal-title":"Eur Urol"},{"issue":"12","key":"4070_CR2","doi-asserted-by":"publisher","first-page":"e2348057","DOI":"10.1001\/jamanetworkopen.2023.48057","volume":"6","author":"S Khan","year":"2023","unstructured":"Khan S et al (2023) Local treatment and treatment-related adverse effects among patients with advanced prostate cancer. JAMA Netw Open 6(12):e2348057","journal-title":"JAMA Netw Open"},{"issue":"2","key":"4070_CR3","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1038\/s41391-021-00439-9","volume":"26","author":"MG Parry","year":"2023","unstructured":"Parry MG et al (2023) Determinants of variation in radical local treatment for men with high-risk localised or locally advanced prostate cancer in England. Prostate Cancer Prostatic Dis 26(2):257\u2013263","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"2","key":"4070_CR4","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1038\/s41391-023-00712-z","volume":"27","author":"ND Shore","year":"2024","unstructured":"Shore ND et al (2024) Biochemical recurrence in patients with prostate cancer after primary definitive therapy: treatment based on risk stratification. Prostate Cancer Prostatic Dis 27(2):192\u2013201","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"3","key":"4070_CR5","first-page":"365","volume":"4","author":"T Chandrasekar","year":"2015","unstructured":"Chandrasekar T et al (2015) Mechanisms of resistance in castration-resistant prostate cancer (CRPC). Transl Androl Urol 4(3):365\u2013380","journal-title":"Transl Androl Urol"},{"issue":"24","key":"4070_CR6","doi-asserted-by":"publisher","first-page":"2532","DOI":"10.1001\/jama.2017.7248","volume":"317","author":"MS Litwin","year":"2017","unstructured":"Litwin MS, Tan HJ (2017) The diagnosis and treatment of prostate cancer: a review. JAMA 317(24):2532\u20132542","journal-title":"JAMA"},{"issue":"6596","key":"4070_CR7","doi-asserted-by":"publisher","first-page":"eabe1505","DOI":"10.1126\/science.abe1505","volume":"376","author":"F Tang","year":"2022","unstructured":"Tang F et al (2022) Chromatin profiles classify castration-resistant prostate cancers suggesting therapeutic targets. Science 376(6596):eabe1505","journal-title":"Science"},{"issue":"10","key":"4070_CR8","doi-asserted-by":"publisher","first-page":"4492","DOI":"10.1172\/JCI128212","volume":"129","author":"MP Labrecque","year":"2019","unstructured":"Labrecque MP et al (2019) Molecular profiling stratifies diverse phenotypes of treatment-refractory metastatic castration-resistant prostate cancer. J Clin Invest 129(10):4492\u20134505","journal-title":"J Clin Invest"},{"issue":"6","key":"4070_CR9","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1016\/j.ccell.2023.04.011","volume":"41","author":"J Li","year":"2023","unstructured":"Li J et al (2023) Remodeling of the immune and stromal cell compartment by PD-1 blockade in mismatch repair-deficient colorectal cancer. Cancer Cell 41(6):1152-1169.e7","journal-title":"Cancer Cell"},{"issue":"8","key":"4070_CR10","doi-asserted-by":"publisher","first-page":"2930","DOI":"10.1172\/JCI91190","volume":"127","author":"M Ayers","year":"2017","unstructured":"Ayers M et al (2017) IFN-gamma-related mRNA profile predicts clinical response to PD-1 blockade. J Clin Invest 127(8):2930\u20132940","journal-title":"J Clin Invest"},{"issue":"8","key":"4070_CR11","doi-asserted-by":"publisher","first-page":"103666","DOI":"10.1016\/j.drudis.2023.103666","volume":"28","author":"Z Peng","year":"2023","unstructured":"Peng Z et al (2023) PD-1\/PD-L1 immune checkpoint blockade in ovarian cancer: dilemmas and opportunities. Drug Discov Today 28(8):103666","journal-title":"Drug Discov Today"},{"issue":"3","key":"4070_CR12","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1038\/s41391-021-00340-5","volume":"24","author":"J Stultz","year":"2021","unstructured":"Stultz J, Fong L (2021) How to turn up the heat on the cold immune microenvironment of metastatic prostate cancer. Prostate Cancer Prostatic Dis 24(3):697\u2013717","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"3","key":"4070_CR13","doi-asserted-by":"publisher","first-page":"1880","DOI":"10.3390\/ijms25031880","volume":"25","author":"K Zhang","year":"2024","unstructured":"Zhang K et al (2024) The XCL1-Mediated DNA vaccine targeting type 1 conventional dendritic cells combined with gemcitabine and anti-PD1 antibody induces potent antitumor immunity in a mouse lung cancer model. Int J Mol Sci 25(3):1880","journal-title":"Int J Mol Sci"},{"issue":"8","key":"4070_CR14","doi-asserted-by":"publisher","first-page":"2182","DOI":"10.1002\/ijc.32855","volume":"146","author":"WC Chou","year":"2020","unstructured":"Chou WC et al (2020) A functional variant near XCL1 gene improves breast cancer survival via promoting cancer immunity. Int J Cancer 146(8):2182\u20132193","journal-title":"Int J Cancer"},{"issue":"12","key":"4070_CR15","doi-asserted-by":"publisher","first-page":"2015","DOI":"10.1007\/s00277-017-3142-3","volume":"96","author":"CH Gutierrez-Aguirre","year":"2017","unstructured":"Gutierrez-Aguirre CH et al (2017) The prognostic significance of serum XCL1 concentration in patients with acute lymphoblastic leukemia: a pilot study. Ann Hematol 96(12):2015\u20132024","journal-title":"Ann Hematol"},{"key":"4070_CR16","doi-asserted-by":"publisher","first-page":"113250","DOI":"10.1016\/j.biopha.2022.113250","volume":"152","author":"J Xia","year":"2022","unstructured":"Xia J et al (2022) Recent progress of dendritic cell-derived exosomes (Dex) as an anti-cancer nanovaccine. Biomed Pharmacother 152:113250","journal-title":"Biomed Pharmacother"},{"issue":"1","key":"4070_CR17","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1007\/s10753-012-9539-1","volume":"36","author":"W Yin","year":"2013","unstructured":"Yin W et al (2013) Immature dendritic cell-derived exosomes: a promise subcellular vaccine for autoimmunity. Inflammation 36(1):232\u2013240","journal-title":"Inflammation"},{"issue":"9","key":"4070_CR18","doi-asserted-by":"publisher","first-page":"e12360","DOI":"10.1002\/jev2.12360","volume":"12","author":"X Wang","year":"2023","unstructured":"Wang X et al (2023) Tumor vaccine based on extracellular vesicles derived from gammadelta-T cells exerts dual antitumor activities. J Extracell Vesicles 12(9):e12360","journal-title":"J Extracell Vesicles"},{"issue":"8","key":"4070_CR19","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1038\/nrc2167","volume":"7","author":"L Kelland","year":"2007","unstructured":"Kelland L (2007) The resurgence of platinum-based cancer chemotherapy. Nat Rev Cancer 7(8):573\u2013584","journal-title":"Nat Rev Cancer"},{"issue":"5","key":"4070_CR20","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1038\/s41587-021-01072-6","volume":"40","author":"M Arnaud","year":"2022","unstructured":"Arnaud M et al (2022) Sensitive identification of neoantigens and cognate TCRs in human solid tumors. Nat Biotechnol 40(5):656\u2013660","journal-title":"Nat Biotechnol"},{"issue":"9","key":"4070_CR21","doi-asserted-by":"publisher","first-page":"3066","DOI":"10.1016\/j.ymthe.2022.06.013","volume":"30","author":"Q Cheng","year":"2022","unstructured":"Cheng Q et al (2022) Eliciting anti-cancer immunity by genetically engineered multifunctional exosomes. Mol Ther 30(9):3066\u20133077","journal-title":"Mol Ther"},{"issue":"12","key":"4070_CR22","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1002\/pros.20793","volume":"68","author":"J Sun","year":"2008","unstructured":"Sun J et al (2008) Cumulative effect of five genetic variants on prostate cancer risk in multiple study populations. Prostate 68(12):1257\u20131262","journal-title":"Prostate"},{"issue":"7","key":"4070_CR23","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1038\/nrc1389","volume":"4","author":"LN Kolonel","year":"2004","unstructured":"Kolonel LN, Altshuler D, Henderson BE (2004) The multiethnic cohort study: exploring genes, lifestyle and cancer risk. Nat Rev Cancer 4(7):519\u2013527","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"4070_CR24","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1023\/A:1020110718701","volume":"21","author":"WG Nelson","year":"2002","unstructured":"Nelson WG, DeWeese TL, DeMarzo AM (2002) The diet, prostate inflammation, and the development of prostate cancer. Cancer Metastasis Rev 21(1):3\u201316","journal-title":"Cancer Metastasis Rev"},{"issue":"8","key":"4070_CR25","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1084\/jem.20042028","volume":"201","author":"V Bronte","year":"2005","unstructured":"Bronte V et al (2005) Boosting antitumor responses of T lymphocytes infiltrating human prostate cancers. J Exp Med 201(8):1257\u20131268","journal-title":"J Exp Med"},{"issue":"1","key":"4070_CR26","doi-asserted-by":"publisher","first-page":"7281","DOI":"10.1038\/s41467-022-34871-9","volume":"13","author":"N Li","year":"2022","unstructured":"Li N et al (2022) ARID1A loss induces polymorphonuclear myeloid-derived suppressor cell chemotaxis and promotes prostate cancer progression. Nat Commun 13(1):7281","journal-title":"Nat Commun"},{"issue":"16","key":"4070_CR27","doi-asserted-by":"publisher","first-page":"8849","DOI":"10.3390\/ijms23168849","volume":"23","author":"S Radej","year":"2022","unstructured":"Radej S, Szewc M, Maciejewski R (2022) Prostate infiltration by Treg and Th17 cells as an immune response to Propionibacterium acnes infection in the course of benign prostatic hyperplasia and prostate cancer. Int J Mol Sci 23(16):8849","journal-title":"Int J Mol Sci"},{"issue":"1","key":"4070_CR28","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.critrevonc.2014.05.011","volume":"92","author":"E Ottley","year":"2014","unstructured":"Ottley E, Gold E (2014) microRNA and non-canonical TGF-beta signalling: implications for prostate cancer therapy. Crit Rev Oncol Hematol 92(1):49\u201360","journal-title":"Crit Rev Oncol Hematol"},{"issue":"9","key":"4070_CR29","doi-asserted-by":"publisher","first-page":"3401","DOI":"10.1172\/JCI80009","volume":"125","author":"CJ Melief","year":"2015","unstructured":"Melief CJ et al (2015) Therapeutic cancer vaccines. J Clin Invest 125(9):3401\u20133412","journal-title":"J Clin Invest"},{"issue":"9","key":"4070_CR30","doi-asserted-by":"publisher","first-page":"3335","DOI":"10.1172\/JCI83871","volume":"125","author":"Y Yang","year":"2015","unstructured":"Yang Y (2015) Cancer immunotherapy: harnessing the immune system to battle cancer. J Clin Invest 125(9):3335\u20133337","journal-title":"J Clin Invest"},{"issue":"1","key":"4070_CR31","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1038\/s41392-023-01557-7","volume":"8","author":"T Zhao","year":"2023","unstructured":"Zhao T et al (2023) Vaccine adjuvants: mechanisms and platforms. Signal Transduct Target Ther 8(1):283","journal-title":"Signal Transduct Target Ther"},{"issue":"4","key":"4070_CR32","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1172\/JCI81137","volume":"126","author":"JM Pitt","year":"2016","unstructured":"Pitt JM et al (2016) Dendritic cell-derived exosomes for cancer therapy. J Clin Invest 126(4):1224\u20131232","journal-title":"J Clin Invest"},{"key":"4070_CR33","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.3389\/fimmu.2019.01014","volume":"10","author":"R Noubade","year":"2019","unstructured":"Noubade R, Majri-Morrison S, Tarbell KV (2019) Beyond cDC1: emerging roles of DC crosstalk in cancer immunity. Front Immunol 10:1014","journal-title":"Front Immunol"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-025-04070-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00262-025-04070-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-025-04070-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T20:36:19Z","timestamp":1757190979000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00262-025-04070-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,18]]},"references-count":33,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2025,8]]}},"alternative-id":["4070"],"URL":"https:\/\/doi.org\/10.1007\/s00262-025-04070-8","relation":{},"ISSN":["1432-0851"],"issn-type":[{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,18]]},"assertion":[{"value":"12 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interests"}},{"value":"Animal studies were approved by the Committee on Animal Research and Ethics of Tianjin Medical University General hospital, and all protocols conformed to the Guidelines for Ethical Conduct in the Care and Use of Nonhuman Animals in Research.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}],"article-number":"242"}}